Research and development

The European Medicines Agency (EMA) provides guidance and support to medicine developers. This includes scientific and regulatory information on how to design and run clinical trials, compliance standards, and obligations and incentives for developers of specialised medicines.

In this section

Early development advice services

EMA has developed a consolidated list of available guidance and opportunities for interaction in the development phase of a medicinal product.

EMA offers medicine developers several opportunities for early dialogue and consultation before submitting a marketing authorisation application. This is intended to provide regulatory and scientific support to facilitate the preparation of applications and enable a smooth validation and assessment procedure.

In addition to making use of these services, medicine developers can also:

Main procedural advice and guidance for medicine development

AreaGuidanceKey points
Scientific advice for human medicinesScientific Advice general informationScientific advice is advice to a medicine developer on the appropriate tests and studies in the development of a medicine
PDF iconGuidance for applicants seeking scientific advice and protocol assistance Protocol assistance is a special form of scientific advice, reserved for medicines with an orphan designation
How to submit a requestProcedural advice for requestin scientific advice and protocol assistance
PDF iconParallel EMA-United States (US) Food and Drug Administration (FDA) scientific advice Parallel EMA-FDA scientific advice should focus primarily on important breakthrough drugs or important safety issues
PDF iconParallel consultation with regulators and health technology assessment bodies Provides feedback from regulators and HTA bodies at the same time, at any point in the developmental lifecycle of medicines.
Paediatric developmentGeneral informationDefinitions, links to submission templates and deadline, and further information on paediatric procedures
European Commission Guideline on PIP/waiver applicationsGuideline from the European Commission on the format and content of applications for agreement or modification of a paediatric investigation plan (PIP)/waiver/modification
Questions and answersProcedural advice for PIP/waiver/modification submissions
Orphan drug designationGeneral information and guidanceHow to apply, prevalence considerations, medical plausibility and significant benefit guidance
European Commission Guideline on orphan drug designation applicationsGuideline on the format and content of applications for designation as orphan product
Innovation task force (ITF)General informationIncludes the PDF iconITF mandate , guidance on how to apply for an ITF briefing meeting for human or veterinary development, and information on advanced therapy classification
PRIME scheme (PRIority MEdicines)PRIME general informationPRIME provides enhanced support for the development of medicines that target an unmet medical need, that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options
PDF iconGuidance EMA guidance on the scope and features of PRIME
Qualification of novel methodologiesGeneral informationScientific advice to support the qualification of innovative development methods (rather than a specific product) for a specific intended use in the context of research and development into pharmaceuticals
PDF iconGuidance Procedural advice


SME support


SME supportRegulatory and administrative assistance by phone, email or teleconference, including SME office briefing meetings to discuss the regulatory strategy of a human or veterinary medicinal product and navigate the range of procedures and incentives. Quarterly newsletters, info days and training
PDF iconUser Guide for SMEs Provides an overview of procedures to support research and development activities and regulatory requirements to obtain a marketing authorisation
Applying for SME statusIncludes the SME declaration form and guidance for enterprises applying for SME status before requesting financial or administrative assistance from the Agency

Opportunities to interact with EMA during the development of a medicine

AreaType of interactionKey points
Scientific advice for human medicinesPresubmission meeting for scientific advice or protocol assistanceAim: to facilitate validation and discuss the proposed questions. Submit a to approximately seven weeks in advance before the intended submission date
Paediatric development
Presubmission meetingAim: to ensure smooth validation. Request a presubmission meeting with PDF iconletter of intent to, at least two months prior to PIP/waiver submission. See also: regulatory Q&A
Clarification of the PDCO requests for modificationAim: to clarify any details of the PDCO's requests for modification, during clock-stop. Request to See also: regulatory Q&A
Orphan drug designationPresubmission meetingAim: to ensure smooth validation. Request a presubmission meeting with an email to, at least two months prior to submission of the orphan designation application
ITFITF briefing meetingSend a request form to for human medicines (or for veterinary medicines)
PRIME schemeQueriesPresubmission meetings are not held for PRIME. Queries prior to submission of PRIME eligibility requests can be addressed to
Qualification of novel methodologiesPreparatory meetingRequest a preparatory meeting sending the Microsoft Office document iconEMA letter of intent template or the Microsoft Office document iconjoint EMA-FDA letter of intent template to


SME support


SME office briefing meeting

Aim: to discuss the regulatory strategy of a product and navigate the range of procedures and incentives available to support development and authorisation. Contact the SME office on +31 (0)88 781 8787 or



How useful was this page?

Add your rating
7 ratings
5 ratings
5 ratings
3 ratings
12 ratings